KIM, Joong Kyu,김중규,BYUN, Sang Soon,변상순,LEE, Hyuk Joon,이혁준,KIM, Do Yun,김도윤,KIM, Yeun Ju,김연주,CHOI, Jin Hee,최진희,NAHM, Kyung Hee,남경희,NAM, Ju Ryung,남주령,JEONG, Jong Geun,정종근,JEONG, Bo Young,정보영,LEE, Eun Jin
申请号：
KRKR2013/010589
公开号：
WO2014/081202A1
申请日:
2013.11.20
申请国别(地区):
KR
年份:
2014
代理人:
摘要：
The present invention relates to an antibody targeting VEGFR-2, and more particularly a dual-target antibody of novel form in which calcium-binding EGF-like domains 11 and 12 of human Notch1 are bound to the N-terminal of the Tanibirumab light chain, a gene coding for same, a recombinant expression vector comprising the gene, host cells that have been genetically modified by using the recombinant expression vector and a method of producing a dual-target antibody by culturing the host cells, a pharmaceutical composition comprising the dual-target antibody, and a method for measuring the DLL4 antagonist efficacy of the dual-target antibody wherein Notch 1 activity is measured by the co-culturing of human umbilical endothelial cells (HUVEC) and a cell strain expressing human DLL4(hDLL4). The dual-target antibody according to the present invention has the advantages that, by more effectively simultaneously disrupting signal transmission following two different pathways of VEGF/VEGFR-2 and DLL4/Notch1, it is possible to treat various diseases associated with vasculogenesis such as tumours and, more particularly, possible to overcome the resistance that occurs following the use of a neovascular therapeutic agent alone, and that, by directly targeting cancer stem cells, it is possible to fundamentally prevent the recurrence of cancer.La présente invention concerne un anticorps ciblant le VEGFR-2 et plus particulièrement un anticorps à double cible d'une nouvelle forme, les domaines 11 et 12 de type EGF liant le calcium de Notch1 humain étant liés à l'extrémité N de la chaîne légère de Tanibirumab, un gène codant pour celui-ci, un vecteur d'expression recombinant comprenant le gène, des cellules hôtes qui ont été modifiées génétiquement à l'aide du vecteur d'expression recombinant et un procédé de production d'un anticorps à double cible par culture des cellules hôtes, une composition pharmaceutique comprenant l'anticorps à double cible et un procédé pour mesurer l'efficaci
